# An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease

> **NCT02293915** · PHASE3 · COMPLETED · sponsor: **Shanghai Greenvalley Pharmaceutical Co., Ltd.** · enrollment: 818 (actual)

## Conditions studied

- Mild to Moderate Alzheimer Disease
- Cognitive Impairment

## Interventions

- **DRUG:** Sodium oligo-mannurarate 900mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02293915
- **Lead sponsor:** Shanghai Greenvalley Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-01
- **Primary completion:** 2018-06-29
- **Final completion:** 2018-09-28
- **Target enrollment:** 818 (ACTUAL)
- **Last updated:** 2018-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293915, "An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02293915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*